A securities class action lawsuit has been filed against Dynavax Technologies, Inc. (NASDAQ: DVAX) in connection to the allegations involving securities sold between March 10, 2014 and November 11, 2016. Fitapelli Kurta is interested in speaking to aggrieved investors who have complaints regarding Dynavax Technologies (DVAX) and wish to serve as the lead plaintiff.
The complaint specifically concerns allegations that the Dynavax Technologies (DVAX) failed to disclose and/or made false or misleading statements with respect to the fact that the phase 3 HBV-23 clinical trial of HEPLISAV-B, its lead vaccine offering, was designed in a manner that was not in accordance with the Food and Drug Administration’s concerns documented in a 2013 Complete Response Letter; that Dynavax did not offer the FDA adequate information in a Revised Biologics License Application for HEPLISAV-B; that it will not have adequate resources to further the program absent FDA support; and that these false and/or misleading statements and/or failures to disclose allegedly resulted in statements related to Dynavax Technologies’ business, operations and prospects being false and/or misleading themselves.
According to the company’s website, Dynavax Technologies (DVAX) is “clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer.” The company develops “immunotherapies based on cutting-edge Toll-Like Receptor (TLR) biology and its ability to modulate the immune system.” The company’s website describes its vision thusly: “We are leaders in utilizing the innate immune system on behalf of patients to address unmet clinical needs. We are committed to a rigorous approach to drug development in the field of TLR biology and immune system modulation to attack the challenges of infectious and inflammatory diseases and cancer.” It trades on the NASDAQ exchange under DVAX.
A class action lawsuit has already been filed in connection with DVAX. If you wish to serve as lead plaintiff in the Dynavax Technologies’ lawsuit, you must move the Court no later than January 17, 2017. If you wish to join the litigation, please contract Marc Fitapelli at 212-658-1501 or Jonathan Kurta at 212-658-1502. There is no cost or obligation to you and your ability to share in any recovery does not require that you serve as a lead plaintiff.